Home

2024 Year in Review

For 40 years, the Society for Immunotherapy of Cancer (SITC) has been dedicated to improving patient outcomes by advancing the science, development and application of cancer immunotherapy. A major milestone of 2024 was the unveiling of SITC’s three-year strategic plan, which serves as a beacon for society initiatives lighting the way for the next wave of immuno-oncology discoveries. To accelerate this vision, SITC launched the #SITCQuestfor100 initiative, aiming for 100 novel IO agents to be approved by 2034. By the end of last year, the IO community had reason to celebrate, with six FDA approvals of novel IO therapies.

Read full letter >

#SITCQuestfor100

With six transformative, innovative, and diverse strategic goals, SITC set a vision for 100 novel immuno-oncology agents approved by 2034. Join our quest to develop a diverse portfolio of agents, expand into earlier lines of therapy, explore AI solutions, and broaden our community tent.

Learn More

Numbers at a Glance

Total Members: 4467
  • 1,068 Student Members
  • 958 International Members

Total Volunteers: 2484
  • 504 Committee members
  • 26 Committees
  • 2 Task Forces

Learn More

Strategic Goals

Education and Scientific Exchange

Serve as the leading resource for information and education on cancer immunotherapy.

Add link to resource here

Professional Standards

Set industry standards for the field of cancer immunotherapy.

Add link to resource here

Global Access and Impact

Advance the science and application of, and equitable access to, cancer immunotherapy worldwide to eliminate disparities and improve outcomes.

Add link to resource here

Policy and Advocacy

Inform and influence the research, regulation, quality of patient care and equity of patient access impacted by public policy.

Add link to resource here

Science and Research

Challenge the thinking, seek and advance the best research to improve outcomes and develop tumor immunology and cancer immunotherapy.

Add link to resource here

Leadership Development

Cultivate the next generation of diverse leaders and innovators in tumor immunology and cancer immunotherapy.

Add link to resource here

Diversity, Equity & Inclusion

Diversity, equity, and inclusion (DEI) aren’t just single initiatives or individual programs for SITC: they are a core value, integrated into everything the society does and led by a passionate committee of dedicated volunteers.


Image card link goes here*

Forward Fund

The SITC Forward Fund enables SITC to further the society’s mission and expand the knowledge of and interest in cancer immunotherapy. With the investment from the Forward Fund, SITC has awarded more than $6 million in research funding to early career investigators in the last decade. In 2024, SITC supported nearly 80 awards for early career scientists.

Image card link goes here*

Honors and Recognition

Each year, SITC celebrates legends in the field who have contributed immeasurably to advancing the science and application of immunotherapy. These individuals serve as a source of inspiration to the next generation and a represent decades of progress for cancer patients everywhere.


Image card link goes here*